What is Qdenga?
Qdenga (TAK-003) is a dengue vaccine developed by Takeda Pharmaceutical Company, Japan. It has been approved in more than 40 countries worldwide and has received WHO prequalification. CDSCO's approval makes it India's first licensed dengue vaccine. Importantly, unlike the earlier Dengvaxia vaccine, Qdenga does not require prior screening for previous dengue infection before administration, making it more broadly applicable.
Understanding Dengue and Its Serotypes
- Dengue is a mosquito-borne viral disease transmitted by the Aedes aegypti mosquito.
- It has four distinct serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.
- Infection with one serotype provides lasting immunity only against that specific serotype.
- A second infection with a different serotype may lead to severe dengue due to Antibody-Dependent Enhancement (ADE).
- ADE means antibodies from the first infection can actually worsen the second infection, leading to dengue haemorrhagic fever or dengue shock syndrome.
| Serotype | Protection Level | Notes |
|---|---|---|
| DENV-1 | Strong protection | Robust clinical trial evidence |
| DENV-2 | Strong protection | Especially effective in previously infected individuals |
| DENV-3 | More limited and uncertain | Reduced efficacy in dengue-naïve individuals |
| DENV-4 | More limited and uncertain | Limited clinical data in naïve populations |
✅ Benefits of Qdenga
- India's first licensed dengue vaccine — historic milestone
- Does not require prior dengue screening
- WHO prequalification ensures quality standards
- Reduces severe dengue and hospitalisation
- Protects high-risk urban and semi-urban populations
- Complements surveillance and vector control
⚠ Key Concerns
- Uneven protection across all four serotypes
- Limited efficacy against DENV-3 and DENV-4 in naïve persons
- DENV-3 dominance could reduce overall effectiveness
- High cost may exclude economically weaker populations
- Ensuring completion of both doses on schedule
- Risk of complacency in mosquito control efforts
Critical Distinction for Prelims and Mains
- Dengvaxia (Sanofi Pasteur) — requires prior testing to confirm previous dengue infection before vaccination; risk of severe dengue in dengue-naïve recipients.
- Qdenga (Takeda) — does NOT require prior screening for previous dengue infection, making it more broadly deployable in public health programmes.
- Qdenga's broader eligibility makes it a more practical vaccine for India's high-burden dengue settings.
- Affordable Access — Government must negotiate procurement at subsidised rates and consider including Qdenga in universal immunisation programmes for high-risk zones.
- Continue Vector Control — Vaccination must not replace mosquito control — Aedes breeding site elimination, fogging and community cleanliness remain essential.
- Two-Dose Completion — Public awareness programmes must emphasise the importance of completing both doses three months apart for full protection.
- Serotype Surveillance — Continuously monitor circulating dengue serotypes to assess and adapt vaccine effectiveness in real-world settings.
- Integrated Strategy — Integrate vaccination with improved diagnostics, strengthened hospital capacity and evidence-based case management protocols.
📌 Prelims Quick Facts
1. It is India's first licensed dengue vaccine.
2. It requires prior screening for previous dengue infection before administration.
3. It is administered in two doses.
Which of the statements given above is/are correct?
Correct Answer: B — 1 and 3 only
- Statement 1 is correct. Qdenga, approved by India's CDSCO, is the first licensed dengue vaccine in India, marking a significant milestone in the country's dengue prevention strategy.
- Statement 2 is incorrect. Unlike Dengvaxia, which requires prior screening to confirm previous dengue infection, Qdenga does NOT require prior dengue screening before administration, making it more broadly applicable.
- Statement 3 is correct. Qdenga is administered as a two-dose schedule, with the two doses given three months apart to provide optimal protection.
Mains Question — 10 Marks | 150 Words
Model Answer
The approval of Qdenga (TAK-003) by India's CDSCO marks a significant advancement in dengue prevention. As India's first licensed dengue vaccine with WHO prequalification and approval in over 40 countries, it offers a new tool to reduce the burden of a disease that causes hundreds of thousands of hospitalisations annually. Crucially, unlike Dengvaxia, Qdenga does not require prior screening for previous dengue infection, making it more deployable in India's public health systems.
However, Qdenga's limitations must be clearly understood. Clinical evidence shows strong protection against DENV-1 and DENV-2 but more uncertain and limited protection against DENV-3 and DENV-4, particularly in dengue-naïve individuals. If DENV-3 or DENV-4 become the dominant circulating serotypes in India, the vaccine's population-level effectiveness could be substantially lower than expected. Affordability is another critical concern — if cost prevents the most vulnerable populations from accessing Qdenga, the vaccine's public health impact will be severely limited. The two-dose schedule also creates a risk of incomplete vaccination.
Dengue control must therefore remain integrated and comprehensive. Vaccination cannot substitute for Aedes mosquito control — breeding site elimination, community sanitation, fogging and public awareness remain essential. Government must negotiate subsidised procurement and consider universal immunisation in high-burden zones. Continuous serotype surveillance will be critical to monitor real-world effectiveness. Strengthening diagnostics and clinical management capacity will ensure that the vaccine's benefits are maximised within a broader, evidence-based dengue control strategy.